Take a look at our capital structure - no expansion since listing some 12 or so years ago. No debt and substantial cash in hand.
However, the company's software suite has been kept fully up to date in terms of technology and functionality plus - a new product - Visage - a truly market leading product that is being successfully rolled out in North America and Europe.
This speaks very highly to the vision, management and technical skills embedded in this company.
PME topped $2 per share some years ago with a much less impressive product suite than what is presented today. If we were a northern hemisphere domiciled software/medical company where businesses like PME are better understood, our sp could be headed for double figures.
This is an opinion based on generally available information - not advice.
PME Price at posting:
95.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)